Calando Pharmaceuticals is focused on developing targeted therapeutics that take advantage of the potential of its patented and proprietary cyclodextrin-based polymer technologies for the development of nanoparticle therapeutics. Our lead RNAi product candidate, CALAA-01, entered the clinic in April 2008.